OvaScience Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
OvaScience Inc
TickerTPST
CIK #0001544227
CUSIP87978U108
SectorLife Sciences - In Vitro & In Vivo Diagnostic Substances
Address215 First Street Suite 240, Cambridge, MA 02142
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Tempest Therapeutics Inc 2022-05-11 15.0 M Exemption: 506(b) · Duration: One year or less · Revenue: No Revenues
OvaScience Inc 2013-03-28 35.0 M Exemption: 506 · Duration: One year or less · Commission: $2,099,995 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001544227] 10-K
[0001544227] 10-Q
[0001544227] 3
[0001544227] 4
[0001544227] 8-K
[0001544227] D
[0001544227] SC 13D
[0001544227] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Angel Matthew Tempest Therapeutics Inc [2026-02-10] 0.0
Sabby Management LLC Tempest Therapeutics Inc [2026-01-21] 0.0
EcoR1 Capital LLC Tempest Therapeutics Inc [2023-02-14] 0.99
Versant Venture Capital VI LP Tempest Therapeutics Inc [2022-05-09] 11.0
LAV Regulus Ltd Tempest Therapeutics Inc [2022-02-17] 2.2
Versant Venture Capital VI LP Tempest Therapeutics Inc [2022-02-11] 14.4
Rock Springs Capital Management LP Tempest Therapeutics Inc [2022-01-03] 11.48
Rock Springs Capital Management LP Tempest Therapeutics Inc [2021-07-08] 0.68
FMR LLC Tempest Therapeutics Inc [2021-07-06] 0.0
Ikarian Capital LLC Millendo Therapeutics Inc [2021-04-07] 7.1
Citadel Advisors LLC Millendo Therapeutics Inc [2021-03-16] 4.1
New Enterprise Associates 15 LP Millendo Therapeutics Inc [2018-12-18] 13.7
Roche Finance Ltd Millendo Therapeutics Inc [2018-12-17] 5.9
SHAM Innovation Sante SAS Millendo Therapeutics Inc [2018-12-17] 5.3
Frazier Healthcare VI LP Millendo Therapeutics Inc [2018-12-17] 10.8
Great Point Partners LLC Millendo Therapeutics Inc [2018-12-17] 0.95
Bpifrance Participations Sa Millendo Therapeutics Inc [2018-12-13] 8.4
ProSight Management LP OvaScience Inc [2018-10-26] 5.6
BML Investment Partners LP OvaScience Inc [2018-09-14] 0.47
Hirschman Orin OvaScience Inc [2018-03-29] 6.2
BML Investment Partners LP OvaScience Inc [2018-03-28] 6.4
EcoR1 Capital LLC OvaScience Inc [2017-03-31] 0.9
BlackRock Inc OvaScience Inc [2017-01-30] 5.3
Aldrich Richard OvaScience Inc [2016-04-01] 5.2
Arrowpoint Asset Management LLC OvaScience Inc [2016-02-16] 7.0
Orbis Investment Management Ltd OvaScience Inc [2016-02-16] 7.66
BlackRock Inc OvaScience Inc [2016-01-28] 6.0
Dipp Michelle OvaScience Inc [2015-10-19] 5.18
Prudential Financial Inc OvaScience Inc [2015-02-17] 7.3
Jennison Associates LLC OvaScience Inc [2015-02-11] 7.3
Adage Capital Partners GP LLC OvaScience Inc [2014-03-21] 5.56
Flynn James E OvaScience Inc [2014-03-11] 7.59
Janus Capital Management LLC OvaScience Inc [2014-02-14] 5.9
FMR LLC OvaScience Inc [2013-02-14] 0.0
BBT Fund LP OvaScience Inc [2013-02-12] 3.4
General Catalyst Group V LP OvaScience Inc [2013-02-11] 7.6
Longwood Fund LP OvaScience Inc [2013-02-08] 23.1
Deer VII & Co Ltd OvaScience Inc [2013-02-08] 16.8
Form 3/4/5 Filer 2011 - 2026
Angel Matthew
Tempest Therapeutics Inc
Yee John D
Richey William Drake
Maestas Nicholas
Trojanowski Justin
Raab Michael
Pellizzari Christine A
Nichol Geoffrey
Simantov Ronit
Brady Stephen R
Whiting Samuel
Versant Vantage II LP
Versant Venture Capital IV LP
Versant Side Fund IV LP
Versant Ventures IV LLC
Versant Ventures VI GP LP
Versant Vantage II GP LP
Versant Ventures VI GP-GP LLC
Versant Vantage II GP-GP LLC
Versant Venture Capital VI LP
Dubensky Thomas W
Woiwode Thomas
Lorenzo Pierre
Rock Springs Capital Master Fund LP
Rock Springs Capital Management LP
Rock Springs Capital LLC
Xu Stella
Owens Julia C
Arcudi III Louis J
Minai-Azary Jennifer Lynn
Hedley Mary Lynne
Dable Habib J
Hindman James M
Gallagher Carol Giltner
Nuechterlein Carole
Howe John P MD
Joseph Tamara L
Zeidan Ryan
Arbet-Engels Christophe
Whitcomb Randall W
Mohideen Pharis
Brinza Jeffery M
Sonsini Peter W
Sandell Scott D
Mott David M
Makower Joshua
Makhzoumi Mohamad
Florence Anthony A Jr
Baskett Forest
Barris Peter J
NEA 15 GP LLC
NEA Partners 15 LP
New Enterprise Associates 15 LP
FHM VI LP
FHM VI LLC
Frazier Healthcare VI LP
Aldrich Richard
Fisher Mary
Gillis Jonathan
Kozin Marc D
Kroeger Christopher A
Lillie James Woodruff
Sexton John
Capello Jeffrey D
Malley Thomas
Dipp Michelle
Couturier Christophe
Chapman Paul WD
Stock Harald F
Tzianabos Arthur
Young Jeffrey E
Harding David
McNeely Theresa
Longwood Fund LP
Kraus Stephen
Deer Management Co LLC
Westphal Christoph H
Bleck Christopher A
Lawton Alison Frances
Lindblom Christopher M
Tilly Jonathan L
Simon John G
Orfao David J
GC Entrepreneurs Fund V LP
General Catalyst GP V LLC
General Catalyst Group Management LLC
Fialkow David P
Cutler Joel E
General Catalyst Group V LP
BVP VII Special Opportunity Fund LP
Deer VII & Co Ltd
Deer VII & Co LP
Bessemer Venture Partners VII Institutional LP
Bessemer Venture Partners VII LP
Chappel Scott C
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Angel Matthew
Common Stock
2026-03-24 Buy 231,482 $2.16 500,001
Angel Matthew
Employee Stock Option (right to buy) · derivative
2026-02-04 Grant 269,621 $0.00
Raab Michael
Stock Option (right to buy) · derivative
2026-01-27 Grant 1,230 $0.00
Simantov Ronit
Stock Option (right to buy) · derivative
2026-01-27 Grant 1,230 $0.00
Pellizzari Christine A
Stock Option (right to buy) · derivative
2026-01-27 Grant 1,230 $0.00
Nichol Geoffrey
Stock Option (right to buy) · derivative
2026-01-27 Grant 1,230 $0.00
Maestas Nicholas
Employee Stock Option (right to buy) · derivative
2025-01-02 Grant 200,000 $0.00
Brady Stephen R
Employee Stock Option (right to buy) · derivative
2025-01-02 Grant 550,000 $0.00
Whiting Samuel
Employee Stock Option (right to buy) · derivative
2025-01-02 Grant 270,000 $0.00
Trojanowski Justin
Employee Stock Option (right to buy) · derivative
2025-01-02 Grant 30,000 $0.00
Versant Vantage II LP +8
Common Stock
2024-08-12 Sell 387,999 $1.10 426,799
Versant Vantage II LP +8
Common Stock
2024-08-08 Sell 400,000 $1.35 540,000
Brady Stephen R
Common Stock
2024-07-03 Buy 35,000 $2.11 73,850
Whiting Samuel
Common Stock
2024-07-02 Buy 4,672 $2.13 9,951
Trojanowski Justin
Common Stock
2024-06-28 Buy 7,500 $2.16 16,200
Raab Michael
Stock Option (right to buy) · derivative
2024-06-13 Grant 16,000 $0.00
Nichol Geoffrey
Stock Option (right to buy) · derivative
2024-06-13 Grant 16,000 $0.00
Pellizzari Christine A
Stock Option (right to buy) · derivative
2024-06-13 Grant 16,000 $0.00
Simantov Ronit
Stock Option (right to buy) · derivative
2024-06-13 Grant 16,000 $0.00
Brady Stephen R
Employee Stock Option (right to buy) · derivative
2024-01-03 Grant 250,000 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 22 786,930
2025-12-31 21 787,544
2025-09-30 17 610,824
2025-06-30 21 1,017,744
2025-03-31 26 6,102,974
2024-12-31 37 6,964,455
2024-09-30 30 2,984,509
2024-06-30 25 2,257,438
2024-03-31 31 2,176,690
2023-12-31 34 2,306,657
2023-09-30 25 3,411,773
2023-06-30 23 3,827,439
Form 13F Holdings
Firm Period DFND Voting Shares
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com